Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

Plain-language summary

This study examines the rotational use of the drugs Imatinib and Nilotinib in patients with Philadelphia chromosome/Bcr-Abl positive acute lymphoblastic leukemia (ALL). It enrolled previously untreated patients over 60, or over 18 but unfit for intensive therapy. The study was conducted in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Intervention

Nilotinib, Imatinib

Start date

6/1/2012

Estimated completion

9/1/2020

Countries

Italy

Related genes

Locations

• Ancona, Italy
• Ascoli Piceno, Italy
• Bari, Italy
• Bergamo, Italy
• Bologna, Italy
• Brescia, Italy
• Brindisi, Italy
• Cagliari, Italy
• Catania, Italy
• Ferrara, Italy
• Genova, Italy
• Milan, Italy
• Modena, Italy
• Naples, Italy
• Naples, Italy
• Novara, Italy
• Orbassano, Italy
• Padova, Italy
• Palermo, Italy
• Pavia, Italy
• Pesaro, Italy
• Pescara, Italy
• Piacenza, Italy
• Ravenna, Italy
• Reggio Calabria, Italy
• Rimini, Italy
• Roma, Italy
• Roma, Italy
• Roma, Italy
• Roma, Italy
• Roma, Italy
• Siena, Italy
• Torino, Italy
• Udine, Italy
• Verona, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Previously untreated Ph+ ALL more than 60 years old or more than 18 years old, but unfit for program of intensive therapy and allogeneic SCT